Re-biopsy of tumor tissues to assess the real-time status of ERBB2 expression in endocrine therapy-resistant ER+ breast cancer may be necessary for the decision to use Trastuzumab Deruxtecan, particularly in cases of NUPR1-overexpressing breast tumors. Here, NUPR1 is linked to breast neoplasm.